Find A Research Study
Study Title: A Randomized Phase III Study of Sublobar Resection versus Sublobar Resection plus Brachytherapy in High Risk Patients with Non-Small Cell Lung Cancer (NSCLC),
Category: Cancer, General
Currently accepting participants?
Yes - please read the description below and contact the study coordinator if you are interested.
Principal Investigator: Richard Koehler
Study Coordinator: Travis Doran
Phone: 206-583-6559 Ext.10748
Email: travis.doran@vmmc.org
What is the A Randomized Phase III Study of Sublobar Resection versus Sublobar Resection plus Brachytherapy in High Risk Patients with Non-Small Cell Lung Cancer (NSCLC), study?
Who can participate?
At least 18 years old
No previous internal radiation therapy to the chest
For more information about the eligibility criteria for this trial, contact study coordinator.
Final eligibility for a clinical trial is determined by the health professionals conducting the trial.
What do I have to do as a study participant?
Patients in group one will undergo surgery to remove the tumor.
Patients in group two will undergo surgery as in group one. They will also undergo internal radiation therapy during surgery
Study Summary:
Detailed Study Description:
Study Design: Interventional
Phase of Study: Phase III
Study Type: Interventional
Condition or Study Focus: Lung Cancer
Intervention Type: Surgery with or without brachytherapy
Intervention Name: Sublobar Resection and possible brachytherapy
Gender: Male and Female
Age group: Interventional
Sponsor: American College of Surgeons Oncology Group
Other studies in this category include:
Studies currently accepting study participants:
- A Randomized Phase III Study of Sublobar Resection versus Sublobar Resection plus Brachytherapy in High Risk Patients with Non-Small Cell Lung Cancer (NSCLC),
- A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients for Stage III and IV Head and Neck Carcinomas
- AMC045: HIV-Associated Anal Cancer
- AMC047: AIDS-Associated B-Cell Non-Hodgkin's Lymphoma
- Brain Metastases in NSCLC (RTOG 0320)
- Investigational drug vs. Placebo for Patients with Renal Cell Carcinoma (Kidney Cancer) at High Risk of Recurrence after Surgery
- Lymphoma (S0313)
- Maintenance therapy for advanced ovarian or peritoneal cancer (GOG 0212)
- Newly diagnosed, untreated ovarian or peritoneal cancer (GOG 0218)
- Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer (RTOG 0524)
- PGT307 - Paclitaxel Poliglumex plus Carboplatin for the treatment of non-small cell lung cancer in women.
- Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
- Sorafenib v. Sunitinib v. Placebo for High Risk Renal Cell Carcinoma Patients
- Sorafenib vs Placebo for Hepatocellular Carcinoma
- Stage IV Urothelial Cancer
- SWOG S0016
- Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced RCC Who Failed First-Line Sunitinib
- Trial of FOLFOX with or without cetuximab for colon cancer
- Use of Human Corticotropin-Releasing Factor (hCRF) to Control Brain Swelling (edema) in Brain Tumor Patients
- Weekly Topotecan (HyCamtin®) with Bevacizumab (Avastin®) Ovarian, Fallopian tube and/or Peritoneal Cancer
Studies currently not accepting study participants:
- Methylphenidate in Treating Patients With Fatigue Caused by Cancer
- MK0646 for Patients with Advanced Cancer
- Open Label Study of Human Corticotropin-Releasing Factor (hCRF)
- Phase I, oral agent for Advanced Cancers
- Randomized Study comparing Human Corticotropin-Releasing Factor to Placebo for Patients Requiring High-dose Dexamethasone
- Weekly IV of Hymcamtin in Combination with Carboplatin as Second Line Therapy in Potentially Platinum-Sensitive Reaplased Ovarian Cancer